- Home
- MEGL vs MYNZ Comparison
MEGL vs MYNZ Comparison
Compare MEGL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- MYNZ
- Stock Information
- Founded
- MEGL 2016
- MYNZ 2021
- Country
- MEGL Hong Kong
- MYNZ Germany
- Employees
- MEGL N/A
- MYNZ N/A
- Industry
- MEGL Finance: Consumer Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- MYNZ Health Care
- Exchange
- MEGL Nasdaq
- MYNZ Nasdaq
- Market Cap
- MEGL 6.8M
- MYNZ 7.9M
- IPO Year
- MEGL 2022
- MYNZ 2021
- Fundamental
- Price
- MEGL $1.41
- MYNZ $1.61
- Analyst Decision
- MEGL
- MYNZ Buy
- Analyst Count
- MEGL 0
- MYNZ 2
- Target Price
- MEGL N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- MEGL 35.5K
- MYNZ 525.3K
- Earning Date
- MEGL 12-11-2025
- MYNZ 09-26-2025
- Dividend Yield
- MEGL N/A
- MYNZ N/A
- EPS Growth
- MEGL N/A
- MYNZ N/A
- EPS
- MEGL N/A
- MYNZ N/A
- Revenue
- MEGL $1,296,394.00
- MYNZ $659,935.00
- Revenue This Year
- MEGL N/A
- MYNZ $26.06
- Revenue Next Year
- MEGL N/A
- MYNZ $4.97
- P/E Ratio
- MEGL N/A
- MYNZ N/A
- Revenue Growth
- MEGL N/A
- MYNZ N/A
- 52 Week Low
- MEGL $1.02
- MYNZ $1.28
- 52 Week High
- MEGL $5.52
- MYNZ $14.39
- Technical
- Relative Strength Index (RSI)
- MEGL 41.13
- MYNZ 52.22
- Support Level
- MEGL $1.41
- MYNZ $1.47
- Resistance Level
- MEGL $1.49
- MYNZ $1.73
- Average True Range (ATR)
- MEGL 0.09
- MYNZ 0.15
- MACD
- MEGL -0.02
- MYNZ 0.00
- Stochastic Oscillator
- MEGL 0.04
- MYNZ 72.22
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.